{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T06:27:05Z","timestamp":1782628025151,"version":"3.54.5"},"reference-count":35,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Once\u2010daily abrocitinib treatment provided meaningful improvements in signs and symptoms of moderate\u2010to\u2010severe atopic dermatitis (AD) in randomized controlled studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate proportions of patients with responses meeting higher threshold efficacy responses than commonly used efficacy end points and to determine if these responses were associated with quality\u2010of\u2010life (QoL) benefits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from a phase 2b (NCT02780167) and two phase 3 studies (NCT03349060\/JADE MONO\u20101; NCT03575871\/JADE MONO\u20102) in adult and adolescent patients (<jats:italic>N<\/jats:italic>\u2009=\u2009942) with moderate\u2010to\u2010severe AD receiving once\u2010daily abrocitinib 200\u2009mg, abrocitinib 100\u2009mg or placebo were pooled. Commonly used (Eczema Area and Severity Index [EASI]\u201075 and\u2009\u22654\u2010point improvement in Pruritus Numerical Rating Scale [PP\u2010NRS4]) and higher threshold efficacy end points (EASI\u201090 to &lt;EASI\u2010100, EASI\u2010100 or PP\u2010NRS0\/1 response) were evaluated. Proportions of patients across Children's Dermatology Life Quality Index\/Dermatology Life Quality Index (CDLQI\/DLQI) band descriptors who achieved various efficacy end points were analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>More abrocitinib\u2010treated patients achieved commonly used or higher threshold efficacy end points at week 12 vs<jats:italic>.<\/jats:italic> placebo. More abrocitinib\u2010treated patients who achieved higher threshold efficacy end points reported \u2018no effect\u2019 of AD on QoL (by CDLQI\/DLQI) at week 12 vs<jats:italic>.<\/jats:italic> those who achieved commonly used but not higher threshold efficacy end points (PP\u2010NRS0\/1 vs<jats:italic>.<\/jats:italic> PP\u2010NRS4 but not PP\u2010NRS0\/1 responders [200\u2009mg: 66.3% vs<jats:italic>.<\/jats:italic> 17.5%; 100\u2009mg: 62.1% vs<jats:italic>.<\/jats:italic> 20.0%]; EASI\u2010100, EASI\u201090 to &lt;EASI\u2010100 vs<jats:italic>.<\/jats:italic> EASI\u201075 to &lt;EASI\u201090 responders [200\u2009mg: 67.6%, 48.9% vs<jats:italic>.<\/jats:italic> 28.8%; 100\u2009mg: 63.2%, 48.1% vs<jats:italic>.<\/jats:italic> 36.7%]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Substantial proportions of patients with moderate\u2010to\u2010severe AD receiving abrocitinib met higher threshold efficacy end points, and this was associated with meaningful additional QoL benefits compared with those who did not meet these higher efficacy thresholds. Not only do a substantial proportion of abrocitinib\u2010treated patients achieve higher threshold efficacy end points but they also do so in a similar timeframe as the more commonly used thresholds for efficacy end points.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trials<\/jats:title><jats:p>NCT02780167, NCT03349060 and NCT03575871.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.18170","type":"journal-article","created":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T08:28:55Z","timestamp":1650788935000},"page":"1308-1317","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["High threshold efficacy responses in moderate\u2010to\u2010severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents"],"prefix":"10.1111","volume":"36","author":[{"given":"S.","family":"St\u00e4nder","sequence":"first","affiliation":[{"name":"Department of Dermatology, Center for Chronic Pruritus University Hospital  M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Therapeutics Clinical Research  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"M. J.","family":"Gooderham","sequence":"additional","affiliation":[{"name":"SKiN Centre for Dermatology Queen's University and Probity Medical Research  Peterborough Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"J. I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"The George Washington University School of Medicine and Health Sciences  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3770-1743","authenticated-orcid":false,"given":"J. P.","family":"Thyssen","sequence":"additional","affiliation":[{"name":"Bispebjerg Hospital, University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Biswas","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"DiBonaventura","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Romero","sequence":"additional","affiliation":[{"name":"Pfizer R &amp; D UK Ltd.  Kent UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Farooqui","sequence":"additional","affiliation":[{"name":"Global Product Development Pfizer R &amp; D UK Ltd.  Sandwich UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.08.031"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70536-1"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.028"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.006"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16364"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.10.039"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.010"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17683"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.06.002"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00459-8"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000161"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.325"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000401"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1159"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.178"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.063"},{"key":"e_1_2_7_18_1","unstructured":"Pfizer.Cibinqo 100 mg film\u2010coated tablets (summary of product characteristics). URLhttps:\/\/www.medicines.org.uk\/emc\/product\/12873\/smpc[updated 09\/10\/2021] (last accessed 22 February 2022)."},{"key":"e_1_2_7_19_1","unstructured":"Pfizer.Japan's MHLW approves Pfizer's CIBINQO\u00ae (abrocitinib) for adults and adolescents with moderate to severe atopic dermatitis. URLwww.pfizer.com\/news\/press-release\/press-release-detail\/japans-mhlw-approves-pfizers-cibinqor-abrocitinib-adults[updated 09\/30\/2021] (last accessed 22 February2022)."},{"key":"e_1_2_7_20_1","volume-title":"CIBINQO\u00ae (abrocitinib). Summary of product characteristics (SmPC)","author":"European Medicines Agency","year":"2021"},{"key":"e_1_2_7_21_1","volume-title":"CIBINQO (Abrocitinib) Tablets, for Oral Use [Prescribing Infromation]","author":"Pfizer Inc","year":"2022"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24137"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00754.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8488-5"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.006"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17744"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23621.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.018"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.030"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.042"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2830"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15919"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14163"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18170","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T08:16:17Z","timestamp":1692692177000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/jdv.18170"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18170","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"assertion":[{"value":"2021-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}